Nothing Special   »   [go: up one dir, main page]

DK1708991T3 - Sulfonamid derivater til behandling af sygdomme - Google Patents

Sulfonamid derivater til behandling af sygdomme

Info

Publication number
DK1708991T3
DK1708991T3 DK05702252T DK05702252T DK1708991T3 DK 1708991 T3 DK1708991 T3 DK 1708991T3 DK 05702252 T DK05702252 T DK 05702252T DK 05702252 T DK05702252 T DK 05702252T DK 1708991 T3 DK1708991 T3 DK 1708991T3
Authority
DK
Denmark
Prior art keywords
diseases
treatment
sulfonamide derivatives
sulfonamide
derivatives
Prior art date
Application number
DK05702252T
Other languages
English (en)
Inventor
Alan D Brown
Mark E Bunnage
Paul A Glossop
Kim James
Charlotte A L Lane
Russell A Lewthwaite
Ian B Moses
David A Price
Nicholas M Thomson
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36954179&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1708991(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0406387A external-priority patent/GB0406387D0/en
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DK1708991T3 publication Critical patent/DK1708991T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK05702252T 2004-01-22 2005-01-12 Sulfonamid derivater til behandling af sygdomme DK1708991T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP04290169 2004-01-22
GB0406387A GB0406387D0 (en) 2004-03-22 2004-03-22 Sulfonamide derivatives for the treatment of diseases
US60026004P 2004-08-09 2004-08-09
PCT/IB2005/000086 WO2005080313A2 (en) 2004-01-22 2005-01-12 Sulfonamide derivatives for the treatment of diseases

Publications (1)

Publication Number Publication Date
DK1708991T3 true DK1708991T3 (da) 2008-01-14

Family

ID=36954179

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05702252T DK1708991T3 (da) 2004-01-22 2005-01-12 Sulfonamid derivater til behandling af sygdomme

Country Status (30)

Country Link
US (4) US7244766B2 (da)
EP (1) EP1708991B1 (da)
JP (1) JP4020954B2 (da)
AP (1) AP2359A (da)
AR (1) AR047509A1 (da)
AT (1) ATE375977T1 (da)
AU (1) AU2005214153B2 (da)
BR (1) BRPI0507085A (da)
CA (1) CA2553789C (da)
DE (1) DE602005002930T2 (da)
DK (1) DK1708991T3 (da)
DO (1) DOP2005000006A (da)
EA (1) EA011167B1 (da)
ES (1) ES2293530T3 (da)
GE (1) GEP20094781B (da)
MY (1) MY143390A (da)
NL (1) NL1028087C2 (da)
NO (1) NO20062983L (da)
NZ (1) NZ548318A (da)
OA (1) OA13362A (da)
PA (1) PA8622001A1 (da)
PE (1) PE20051136A1 (da)
PL (1) PL1708991T3 (da)
PT (1) PT1708991E (da)
RS (1) RS50561B (da)
SI (1) SI1708991T1 (da)
TW (1) TWI341831B (da)
UA (1) UA84048C2 (da)
UY (1) UY28721A1 (da)
WO (1) WO2005080313A2 (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS50561B (sr) * 2004-01-22 2010-05-07 Pfizer Inc. Derivati sulfonamida za lečenje bolesti
GB0425054D0 (en) * 2004-03-23 2004-12-15 Pfizer Ltd Formamide derivatives for the treatment of diseases
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
EP1695973A1 (en) * 2005-02-24 2006-08-30 Neuro3D Ocaperidone salt and pharmaceutical compositions containing the same
MX2008000794A (es) * 2005-07-18 2008-03-18 Pfizer Ltd Procedimiento para la preparacion de derivados de sulfonamida.
BRPI0614290A2 (pt) 2005-08-08 2011-03-22 Argenta Discovery Ltd derivados de biciclo [ 2.2.1 ] hept-7-ilamina e seus usos
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
PE20080361A1 (es) 2006-04-21 2008-06-03 Novartis Ag Compuestos derivados de purina como activadores del receptor de adenosina a2a
JP4948913B2 (ja) * 2006-06-16 2012-06-06 上野製薬株式会社 ナフタレンカルボン酸アミドの製造方法
MX2010007604A (es) 2008-01-11 2010-08-02 Novartis Ag Pirimidinas como inhibidores de cinasa.
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
CA2748331C (en) 2008-12-30 2016-08-02 Pulmagen Therapeutics (Inflammation) Limited Sulfonamide compounds for the treatment of respiratory disorders
WO2010136940A1 (en) 2009-05-29 2010-12-02 Pfizer Limited Novel glucocorticoid receptor agonists
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
JP5801997B2 (ja) 2009-07-07 2015-10-28 ファイザー・リミテッドPfizer Limited 薬品の組合せを吸入するための投薬ユニット、投薬ユニットのパック、および吸入器
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
AU2012220572A1 (en) 2011-02-25 2013-08-29 Irm Llc Compounds and compositions as trk inhibitors
WO2013021309A1 (en) 2011-08-11 2013-02-14 Pfizer Limited Intermediate and process for the preparation of a sulfonamide derivative
AU2021296221A1 (en) 2020-06-26 2023-02-02 Mylan Pharma Uk Limited Formulations including 5-(3-(3-hydroxyphenoxy)azetidin-1-yl)-5-methyl-2,2-diphenylhexanamide

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US143034A (en) * 1873-09-23 Improvement in rocking-grates
US229058A (en) * 1880-06-22 spencer
US4404224A (en) 1981-12-02 1983-09-13 American Cyanamid Company Alkanesulfonanilide derivatives and pharmaceutically acceptable acid addition salts thereof for increasing the growth rate and/or improving the lean meat to fat ratio of warm blooded animals
US4540581A (en) 1984-01-31 1985-09-10 Bristol-Myers Company Topical nonsteroidal anti-inflammatory compositions and uses
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5264067A (en) 1992-04-23 1993-11-23 Geber Garment Technology, Inc. Adjustable length carriage compatible for use with differing spreading table widths and types
US5776983A (en) * 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
JPH10218861A (ja) 1997-02-04 1998-08-18 Yamanouchi Pharmaceut Co Ltd 新規なフェネタノール誘導体又はその塩
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
BR9810456A (pt) * 1997-06-27 2001-09-25 Fujisawa Pharmaceutical Co Composto de sulfonamida, método para sua obtenção e seu uso farmacêutico
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
US20020143034A1 (en) * 1998-12-30 2002-10-03 Fujisawa Pharmaceutical Co. Ltd. Aminoalcohol derivatives and their use as beta 3 adrenergic agonists
AUPQ841300A0 (en) 2000-06-27 2000-07-20 Fujisawa Pharmaceutical Co., Ltd. New aminoalcohol derivatives
US6465501B2 (en) 2000-07-17 2002-10-15 Wyeth Azolidines as β3 adrenergic receptor agonists
HRP20000765A2 (en) * 2000-11-10 2002-06-30 Pliva D D Compositions of n-(1-methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridylsulfonamide and cyclic oligosaccharides with increased release
US7048994B2 (en) 2001-02-23 2006-05-23 Teijin Limited Laminated polyester film and magnetic recording medium
US20030229058A1 (en) * 2001-11-13 2003-12-11 Moran Edmund J. Aryl aniline beta2 adrenergic receptor agonists
US20030185700A1 (en) * 2002-03-26 2003-10-02 The Japan Steel Works, Ltd. Heat-resisting steel and method of manufacturing the same
JP2005527618A (ja) * 2002-05-28 2005-09-15 セラヴァンス インコーポレーテッド アルコキシアリールβ2アドレナリン作動性レセプターアゴニスト
EP1477167A1 (en) * 2003-05-15 2004-11-17 Pfizer Limited [(2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propyl] phenyl derivatives as beta2 agonists
RS50561B (sr) * 2004-01-22 2010-05-07 Pfizer Inc. Derivati sulfonamida za lečenje bolesti

Also Published As

Publication number Publication date
ES2293530T3 (es) 2008-03-16
UY28721A1 (es) 2005-08-31
TWI341831B (en) 2011-05-11
PT1708991E (pt) 2007-12-14
RS50561B (sr) 2010-05-07
UA84048C2 (ru) 2008-09-10
AU2005214153A1 (en) 2005-09-01
EP1708991B1 (en) 2007-10-17
DE602005002930T2 (de) 2008-07-24
US8013019B2 (en) 2011-09-06
EP1708991A2 (en) 2006-10-11
TW200530165A (en) 2005-09-16
US20090197912A1 (en) 2009-08-06
US20050182091A1 (en) 2005-08-18
SI1708991T1 (sl) 2008-02-29
AR047509A1 (es) 2006-01-25
WO2005080313A2 (en) 2005-09-01
JP4020954B2 (ja) 2007-12-12
CA2553789C (en) 2011-07-19
PA8622001A1 (es) 2005-08-30
OA13362A (en) 2007-04-13
WO2005080313A3 (en) 2005-12-01
AP2359A (en) 2012-01-30
US20080267970A1 (en) 2008-10-30
BRPI0507085A (pt) 2007-06-19
EA011167B1 (ru) 2009-02-27
US7528170B2 (en) 2009-05-05
NL1028087A1 (nl) 2005-07-25
MY143390A (en) 2011-05-13
PE20051136A1 (es) 2006-02-18
US20100273758A1 (en) 2010-10-28
DE602005002930D1 (de) 2007-11-29
NO20062983L (no) 2006-07-24
DOP2005000006A (es) 2005-07-31
AU2005214153B2 (en) 2008-09-18
EA200601223A1 (ru) 2006-12-29
PL1708991T3 (pl) 2008-02-29
AP2006003669A0 (en) 2006-06-30
NZ548318A (en) 2009-03-31
US7244766B2 (en) 2007-07-17
CA2553789A1 (en) 2005-09-01
WO2005080313A9 (en) 2006-08-31
GEP20094781B (en) 2009-09-25
US7767715B2 (en) 2010-08-03
ATE375977T1 (de) 2007-11-15
JP2007518789A (ja) 2007-07-12
NL1028087C2 (nl) 2006-05-09

Similar Documents

Publication Publication Date Title
DK1708991T3 (da) Sulfonamid derivater til behandling af sygdomme
DK1708992T3 (da) Sulfonamidderivater til behandling af sygdomme
DK1830843T3 (da) Indolidon-derivater til behandling eller forebyggelse af fibrotiske sygdomme
DK1701941T3 (da) Forbindelser til behandling af sygdomme med celleproliferation
DK1833799T3 (da) 3-phenyl-pyrazol derivater, som modulatorer af 5-HT-2a-serotonin receptor nyttig til behandlingen af sygdomme relateret hertil
DK1937633T3 (da) Biphenyloxyeddikesyrederivater til behandling af respiratoriske sygdomme
DK1928438T3 (da) Anvendelse af ibudilast til behandling af stofafhængighed
DK1828164T3 (da) Fremgangsmåde til fremstilling af N-phenylpyrazol-1-carboxamider
DK1778668T3 (da) Fremgangsmåde til fremstilling af dihydropteridion
DK2474321T3 (da) Sammensætninger til behandling af collagenmedierede sygdomme
DK1633726T3 (da) Pyrimidinderivater, der er egnede til behandling af CRTH2-formidlede sygdomme
DK1802579T3 (da) Derivater af 3-arylaminopyridin
DK1716162T3 (da) Phosphonater, amidomonophosphonater, amidobisphosphonater til behandling af virussygdomme
DK1817282T3 (da) Til behandling af respiratoriske sygdomme egnede phenoxy derivater
DK1874781T3 (da) Dihydrothienopyrimidiner til behandling af inflammatoriske sygdomme
DK3456707T3 (da) 4-(p-quinonyl)-2-hydroxybutanamidderivater til behandling af mitokondriesygdomme
DK1776136T3 (da) Behandling af tilstande, der involverer demyelinisering
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
DK1830850T3 (da) Quinolin-derivater til behandling af latent tuberkulose
DK1948615T3 (da) Til behandling af gynækologiske sygdomme egnede pyrazolderivater
DK3403657T3 (da) Anvendelse af oligouronater til behandling af slimhyperviskositet
DK1773787T3 (da) Fremgangsmåde til fremstilling af 3-phenyl(thio)uraciler og -dithiouraciler
DK1962869T3 (da) Behandling af luftvejssygdomme
DK1801108T3 (da) Morpholinforbindelser til behandling af inflammationer.
DK1744781T3 (da) Behandling af infektionssygdomme